Share of Cost, Study Shows Promise For New Drug To Treat Fragile X
Saturday, May. 28th 2011 1:54 PM
The first drug to treat the underlying disorder instead of the symptoms of Fragile X, the most common cause of inherited intellectual disability, shows some promise according to a new study published in the January issue of Science Translational Medicine. Researchers from Rush University Medical Center helped design the study and are now participating in the larger follow-up clinical trial. The data from the early trial of 30 Fragile X patients, found the drug, called AFQ056, made by Novartis Pharmaceuticals, helped improve symptoms in some patients.
Related posts:
- Study Shows Promise For New Drug To Treat Fragile X Study Shows Promise For New Drug To Treat Fragile X...
- Leading Researchers To Share New Treatments At Fragile X International Conference Accelerated research findings leading to potentially significant new treatments for fragile X syndrome (FXS) will be presented to nearly 1,000 family members and professionals at the 12th International Fragile X Conference in Dearborn July 21-25…...
- Share of Cost, Imaging Study Shows Love Can Last Can science prove that romantic love can last? A new study led by Bianca Acevedo, Ph.D., and Arthur Aron, Ph.D., of the Department of Psychology at Stony Brook University, and colleagues, compared the neural correlates of long-term married and in love individuals with individuals who had recently fallen in love. They discovered highly similar brain […]...
- New York Share of Cost, Zegerid OTC Provides Greater And Faster Acid Control Than Prevacid 24HR According To Head-To-Head Clinical Study New York Share of Cost, Zegerid OTC Provides Greater And Faster Acid Control Than Prevacid 24HR According To Head-To-Head Clinical Study: Merck Consumer Care has announced results of a head-to-head clinical study showing that ZEGERID OTC™ offers greater and faster acid control than Prevacid® 24HR. While acid control is an industry standard measure for acid-reducing […]...
- Autism-Related Study Discovers How Drug Interferes With Neuronal Cell Function A York University study has shown for the first time how the drug misoprostol, which has been linked to neurodevelopmental defects associated with autism, interferes with neuronal cell function. It is an important finding because misoprostol is similar in structure to naturally-occurring prostaglandins, which are the key signaling molecules produced by fatty acids in the […]...
- DeepBrain Study Shows That Thinking About God Reduces Distress – But Only For Believers Thinking about God may make you less upset about making errors, according to a new study published in Psychological Science, a journal of the Association for Psychological Science. The researchers measured brain waves for a particular kind of distress-response while participants made mistakes on a test....
- Study Marks The Emergence Of Disease-Modifying Treatments For Autism Spectrum Disorders Study Marks The Emergence Of Disease-Modifying Treatments For Autism Spectrum Disorders...
- Share of Cost, World’s Largest ADHD Study Underway At UQ, Australia Brisbane researchers are almost halfway through the biggest ever study into Attention Deficit Hyperactivity Disorder (ADHD) – and they are seeking additional research participants. Queensland Brain Institute neuroscientists are hoping to study more than 600 families, as they work towards identifying risk genes for the disorder....
- California Share of Cost, Weight Loss And Physical Activity Improve Symptoms Of GERD California Share of Cost, Weight Loss And Physical Activity Improve Symptoms Of GERD: Gastroesophageal reflux disease (GERD) is a debilitating problem for sufferers — heartburn, difficulty swallowing, chest pain and acid reflux....
- Share of Cost, Bristol-Myers Squibb And ADAP Crisis Task Force Announce Enhanced, Multi-year Support For AIDS Drug Assistance Programs (ADAPs) In The United States Bristol-Myers Squibb Company (NYSE: BMY) and the ADAP Crisis Task Force (ACTF) announced an enhanced agreement to support the efforts of AIDS Drug Assistance Programs (ADAPs) to provide antiretroviral medicines to people living with HIV and AIDS....
- Share of Cost, Medi-Cal, NICE Consults On Draft Guideline On Food Allergies In Children NICE has opened the consultation on its draft clinical guideline on the diagnosis and assessment of food allergies in children and young people. Its aim is to support GPs and other health professionals in primary care and community settings in recognising the signs and symptoms of food allergy, by giving clear recommendations on taking allergy-focussed […]...
- Researchers Find More Evidence That Malaria Drug Could Help Combat Cancer, And That Breaks From Treatment Could Improve Results Scientists investigating the cancer-fighting properties of artesunate a drug commonly used to treat malaria have found early evidence that combining it with an existing cancer drug has the potential to make each drug more effective than when used alone. They also found that regular treatment breaks could improve success levels. The findings, recently published in […]...
- Share of Cost, UF Receives $4.7 Million To Study Marijuana’s Role In Immunity Among HIV-positive Adolescents HIV experts at the University of Florida, along with colleagues at the University of South Florida and the University of California, San Diego, have been awarded $4.7 million by the National Institutes of Health to study how the complex interplay between marijuana use and HIV infection can influence the development of neurological disorders in adolescents....
Posted on Saturday, May. 28th 2011 1:54 PM | by Share of Cost | in Share of Cost | No Comments »